Moreover, our findings indicate that suppression of the TBK1/Akt Ser473/Bmi1 Ser316/p16 axis is a potential therapeutic strategy for minimizing RGC senescence in retinal ischemia and glaucoma. Here, CDKN2A is linked to glaucoma.